Stéphane Bancel, Moderna CEO (Charles Krupa/AP Images)

Mod­er­na's bi­va­lent Omi­cron vac­cine se­cures reg­u­la­to­ry OK in UK

Nine months af­ter Omi­cron nabbed the ti­tle of newest Covid-19 virus vari­ant, a vac­cine to bat­tle the new, more con­ta­gious vari­ant has re­ceived a reg­u­la­to­ry nod. But so far, on­ly in the UK.

Mod­er­na an­nounced Mon­day that the UK signed off on its boost­er vac­cine 1273.214, a 50 µg dose and es­sen­tial­ly a 2-in-1. Half of the vac­cine tar­gets the orig­i­nal virus strain, while the oth­er half tar­gets Omi­cron (BA.1). Mod­er­na not­ed that an ex­plorato­ry analy­sis showed a “good im­mune re­sponse” against BA.4 and BA.5, two Omi­cron sub vari­ants that have been pop­ping up more and more fre­quent­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.